IAAF Announces New ATUE Protocol for 2006

January 1, 2006

In response to an increase in the use of Beta-2 Agonists by athletes, the IAAF Council has endorsed a recommendation from the IAAF Medical and Anti-Doping Commission to require more detailed information from applicants who seek an exemption for the use of Beta-2 Agonists for asthma and/or exercise-induced asthma or exercise-induced bronchoconstriction, and/or other clinical respiratory diseases requiring specific treatment.

Applicants seeking the use of the four Beta-2 Agonists (formeterol, salbutamol, salmeterol and terbutaline) will be required to submit the following information:

1. An IAAF Abbreviated TUE Application Form including detailed medical records. The application can be downloaded at www.iaaf.org/antidoping
2. Objective evidence of asthma and/or exercise-induced asthma or exercise-induced bronchoconstriction, and/or other clinical respiratory diseases requiring specific treatment through the provision of test results and supporting documentation as set forth in the provocation test results requirements. ALL TESTS MUST BE PERFORMED AFTER JANUARY 1, 2005.

The IAAF has also developed a Detailed Medical Records form that athletes can take to their physician to have them complete the form and control the amount of detailed medical records that are submitted to the IAAF. This application can be download at www.iaaf.org/antidoping.

For athletes who have well-controlled asthma with negative response to all the tests - the IAAF has acknowledged the exceptional cases of athletes with known, but well-controlled, asthma reporting 'negative' results from the bronchial provocation tests, while applying for the use of inhaled Beta-2 Agonists, the following documentation must be enclosed, in addition to negative results obtained in the bronchial provocation tests: a complete report from personal physician on medical history, including reports on hospital emergency department attendance or admission for acute exacerbations of asthma and on previous treatment with different medications, including systemic corticosteroids, and any additional information that might be helpful for the diagnosis.

Athletes who have questions regarding these changes to the IAAF Protocol are encouraged to contact USADA's Camila Zardo at 719-785-2045 as they begin the application process or the application renewal process.